Nanopublications LDF server

Matches in Nanopublications for { ?s ?p "[In addition, geldanamycin (HSP90 inhibitor) and two CHK1 inhibitors (UCN-01 and SB218078) exhibited a significantly stronger synergism with cisplatin in FA-proficient cells when compared to FA-deficient cells, suggesting a contribution of their FA pathway inhibitory activity to cisplatin sensitization.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }

• NP262257.RAQOKwFs5pS4hz9EYFWTB3VMys6ok6ruzBKlBHNXxZjc4130_assertion description "[In addition, geldanamycin (HSP90 inhibitor) and two CHK1 inhibitors (UCN-01 and SB218078) exhibited a significantly stronger synergism with cisplatin in FA-proficient cells when compared to FA-deficient cells, suggesting a contribution of their FA pathway inhibitory activity to cisplatin sensitization.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP262257.RAQOKwFs5pS4hz9EYFWTB3VMys6ok6ruzBKlBHNXxZjc4130_provenance.
• NP357815.RAcInDLMJf5pjHPOVboo7FzfmdktpjsXEva3Z1cHeRapg130_assertion description "[In addition, geldanamycin (HSP90 inhibitor) and two CHK1 inhibitors (UCN-01 and SB218078) exhibited a significantly stronger synergism with cisplatin in FA-proficient cells when compared to FA-deficient cells, suggesting a contribution of their FA pathway inhibitory activity to cisplatin sensitization.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP357815.RAcInDLMJf5pjHPOVboo7FzfmdktpjsXEva3Z1cHeRapg130_provenance.
• assertion description "[In addition, geldanamycin (HSP90 inhibitor) and two CHK1 inhibitors (UCN-01 and SB218078) exhibited a significantly stronger synergism with cisplatin in FA-proficient cells when compared to FA-deficient cells, suggesting a contribution of their FA pathway inhibitory activity to cisplatin sensitization.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[In addition, geldanamycin (HSP90 inhibitor) and two CHK1 inhibitors (UCN-01 and SB218078) exhibited a significantly stronger synergism with cisplatin in FA-proficient cells when compared to FA-deficient cells, suggesting a contribution of their FA pathway inhibitory activity to cisplatin sensitization.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• NP312972.RAY7QNnCzaTIHI82LEOEwtctcXA7lri6hr15KXK1a9SAw130_assertion description "[In addition, geldanamycin (HSP90 inhibitor) and two CHK1 inhibitors (UCN-01 and SB218078) exhibited a significantly stronger synergism with cisplatin in FA-proficient cells when compared to FA-deficient cells, suggesting a contribution of their FA pathway inhibitory activity to cisplatin sensitization.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP312972.RAY7QNnCzaTIHI82LEOEwtctcXA7lri6hr15KXK1a9SAw130_provenance.
• NP729459.RA8pa5RRVUGMv13LUPvnrpCChcZexPNA9LTcDojaMprWY130_assertion description "[In addition, geldanamycin (HSP90 inhibitor) and two CHK1 inhibitors (UCN-01 and SB218078) exhibited a significantly stronger synergism with cisplatin in FA-proficient cells when compared to FA-deficient cells, suggesting a contribution of their FA pathway inhibitory activity to cisplatin sensitization.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP729459.RA8pa5RRVUGMv13LUPvnrpCChcZexPNA9LTcDojaMprWY130_provenance.
• assertion description "[In addition, geldanamycin (HSP90 inhibitor) and two CHK1 inhibitors (UCN-01 and SB218078) exhibited a significantly stronger synergism with cisplatin in FA-proficient cells when compared to FA-deficient cells, suggesting a contribution of their FA pathway inhibitory activity to cisplatin sensitization.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[In addition, geldanamycin (HSP90 inhibitor) and two CHK1 inhibitors (UCN-01 and SB218078) exhibited a significantly stronger synergism with cisplatin in FA-proficient cells when compared to FA-deficient cells, suggesting a contribution of their FA pathway inhibitory activity to cisplatin sensitization.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[In addition, geldanamycin (HSP90 inhibitor) and two CHK1 inhibitors (UCN-01 and SB218078) exhibited a significantly stronger synergism with cisplatin in FA-proficient cells when compared to FA-deficient cells, suggesting a contribution of their FA pathway inhibitory activity to cisplatin sensitization.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[In addition, geldanamycin (HSP90 inhibitor) and two CHK1 inhibitors (UCN-01 and SB218078) exhibited a significantly stronger synergism with cisplatin in FA-proficient cells when compared to FA-deficient cells, suggesting a contribution of their FA pathway inhibitory activity to cisplatin sensitization.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• NP977832.RAbehrRohTTdNL_HWy3AtwhW1Wur3_VDemL06pCXK1qdE130_assertion description "[In addition, geldanamycin (HSP90 inhibitor) and two CHK1 inhibitors (UCN-01 and SB218078) exhibited a significantly stronger synergism with cisplatin in FA-proficient cells when compared to FA-deficient cells, suggesting a contribution of their FA pathway inhibitory activity to cisplatin sensitization.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP977832.RAbehrRohTTdNL_HWy3AtwhW1Wur3_VDemL06pCXK1qdE130_provenance.
• NP977834.RATWqOj3b59MP104dA8kllwubu4-JYyVLoHJlGdFk-Wcw130_assertion description "[In addition, geldanamycin (HSP90 inhibitor) and two CHK1 inhibitors (UCN-01 and SB218078) exhibited a significantly stronger synergism with cisplatin in FA-proficient cells when compared to FA-deficient cells, suggesting a contribution of their FA pathway inhibitory activity to cisplatin sensitization.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP977834.RATWqOj3b59MP104dA8kllwubu4-JYyVLoHJlGdFk-Wcw130_provenance.
• NP312807.RAuHMvMM2vOyte4_VWGEHOwyWVfZ2xU5GpUFAOeKmoVkI130_assertion description "[In addition, geldanamycin (HSP90 inhibitor) and two CHK1 inhibitors (UCN-01 and SB218078) exhibited a significantly stronger synergism with cisplatin in FA-proficient cells when compared to FA-deficient cells, suggesting a contribution of their FA pathway inhibitory activity to cisplatin sensitization.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP312807.RAuHMvMM2vOyte4_VWGEHOwyWVfZ2xU5GpUFAOeKmoVkI130_provenance.
• NP469043.RAuxXYoBUvaIzU9aWqF7f12R6URLOgSgNYH-2dR4it8t0130_assertion description "[In addition, geldanamycin (HSP90 inhibitor) and two CHK1 inhibitors (UCN-01 and SB218078) exhibited a significantly stronger synergism with cisplatin in FA-proficient cells when compared to FA-deficient cells, suggesting a contribution of their FA pathway inhibitory activity to cisplatin sensitization.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP469043.RAuxXYoBUvaIzU9aWqF7f12R6URLOgSgNYH-2dR4it8t0130_provenance.
• NP469431.RApDftXwTLgcrl9bAGX0QJLAs1XCihCdOj9LG5ogiGNTY130_assertion description "[In addition, geldanamycin (HSP90 inhibitor) and two CHK1 inhibitors (UCN-01 and SB218078) exhibited a significantly stronger synergism with cisplatin in FA-proficient cells when compared to FA-deficient cells, suggesting a contribution of their FA pathway inhibitory activity to cisplatin sensitization.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP469431.RApDftXwTLgcrl9bAGX0QJLAs1XCihCdOj9LG5ogiGNTY130_provenance.
• NP765476.RAAFvohijw5jKrHcWzQALpUZOHvlE3JFeE0TngYDkmguo130_assertion description "[In addition, geldanamycin (HSP90 inhibitor) and two CHK1 inhibitors (UCN-01 and SB218078) exhibited a significantly stronger synergism with cisplatin in FA-proficient cells when compared to FA-deficient cells, suggesting a contribution of their FA pathway inhibitory activity to cisplatin sensitization.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP765476.RAAFvohijw5jKrHcWzQALpUZOHvlE3JFeE0TngYDkmguo130_provenance.
• NP977833.RAip7pBRc5y9jekaJmATlCGcEyzmA9MD3OMuFOK1r2YIE130_assertion description "[In addition, geldanamycin (HSP90 inhibitor) and two CHK1 inhibitors (UCN-01 and SB218078) exhibited a significantly stronger synergism with cisplatin in FA-proficient cells when compared to FA-deficient cells, suggesting a contribution of their FA pathway inhibitory activity to cisplatin sensitization.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP977833.RAip7pBRc5y9jekaJmATlCGcEyzmA9MD3OMuFOK1r2YIE130_provenance.
• NP977838.RAshLV6rRmNPJb_Ud97z5BUeSllKCHRoZIQkx_T4c8eRs130_assertion description "[In addition, geldanamycin (HSP90 inhibitor) and two CHK1 inhibitors (UCN-01 and SB218078) exhibited a significantly stronger synergism with cisplatin in FA-proficient cells when compared to FA-deficient cells, suggesting a contribution of their FA pathway inhibitory activity to cisplatin sensitization.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP977838.RAshLV6rRmNPJb_Ud97z5BUeSllKCHRoZIQkx_T4c8eRs130_provenance.
• NP817084.RANkzl5faAh4mMWxR4p-ugLhDJOe__bcIMkZx_U9pxD6k130_assertion description "[In addition, geldanamycin (HSP90 inhibitor) and two CHK1 inhibitors (UCN-01 and SB218078) exhibited a significantly stronger synergism with cisplatin in FA-proficient cells when compared to FA-deficient cells, suggesting a contribution of their FA pathway inhibitory activity to cisplatin sensitization.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP817084.RANkzl5faAh4mMWxR4p-ugLhDJOe__bcIMkZx_U9pxD6k130_provenance.
• NP977827.RAHkEv4Ihekeq9EyhEjLoyvs3iRKzdEa_77MH7iFrirN8130_assertion description "[In addition, geldanamycin (HSP90 inhibitor) and two CHK1 inhibitors (UCN-01 and SB218078) exhibited a significantly stronger synergism with cisplatin in FA-proficient cells when compared to FA-deficient cells, suggesting a contribution of their FA pathway inhibitory activity to cisplatin sensitization.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP977827.RAHkEv4Ihekeq9EyhEjLoyvs3iRKzdEa_77MH7iFrirN8130_provenance.
• NP765398.RA1bIZQnb0x0g8ln8SLLwsASKtej2ds2oAdYPbaQ5Fi60130_assertion description "[In addition, geldanamycin (HSP90 inhibitor) and two CHK1 inhibitors (UCN-01 and SB218078) exhibited a significantly stronger synergism with cisplatin in FA-proficient cells when compared to FA-deficient cells, suggesting a contribution of their FA pathway inhibitory activity to cisplatin sensitization.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP765398.RA1bIZQnb0x0g8ln8SLLwsASKtej2ds2oAdYPbaQ5Fi60130_provenance.
• NP977839.RA_WTz1XolpFPKvZ_WqJd9yiETZrNOUpuW7MOz9ID6PUk130_assertion description "[In addition, geldanamycin (HSP90 inhibitor) and two CHK1 inhibitors (UCN-01 and SB218078) exhibited a significantly stronger synergism with cisplatin in FA-proficient cells when compared to FA-deficient cells, suggesting a contribution of their FA pathway inhibitory activity to cisplatin sensitization.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP977839.RA_WTz1XolpFPKvZ_WqJd9yiETZrNOUpuW7MOz9ID6PUk130_provenance.